Caribou Biosciences Inc Ordinary Shares CRBU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
-
Caribou Biosciences Gets FDA Fast-Track Designation for Two Candidates
-
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
-
Caribou Biosciences to Participate in Upcoming Investor Conferences
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
-
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
-
Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $1.94
- Day Range
- $1.89–2.01
- 52-Week Range
- $1.50–8.33
- Bid/Ask
- $1.95 / $2.02
- Market Cap
- $178.92 Mil
- Volume/Avg
- 1.3 Mil / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.27
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 137
- Website
- https://www.cariboubio.com
Comparables
Valuation
|
Metric
|
CRBU
|
NTLA
|
REGN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 23.40 |
Price/Book Value | 0.58 | 2.13 | 4.07 |
Price/Sales | 5.27 | 40.74 | 8.84 |
Price/Cash Flow | — | — | 24.89 |
Price/Earnings
CRBU
NTLA
REGN
Financial Strength
|
Metric
|
CRBU
|
NTLA
|
REGN
|
|---|---|---|---|
Quick Ratio | 8.55 | 6.69 | 4.43 |
Current Ratio | 8.75 | 7.21 | 5.44 |
Interest Coverage | — | — | 60.16 |
Quick Ratio
CRBU
NTLA
REGN
Profitability
|
Metric
|
CRBU
|
NTLA
|
REGN
|
|---|---|---|---|
Return on Assets (Normalized) | −27.46% | −28.75% | 15.52% |
Return on Equity (Normalized) | −32.81% | −34.94% | 19.84% |
Return on Invested Capital (Normalized) | −30.37% | −35.82% | 16.15% |
Return on Assets
CRBU
NTLA
REGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xgszzxjq | Hzft | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Pqsykkgf | Nplyrg | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rynktjb | Msqgc | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xqqkkjfyk | Yyqkxp | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Pdsfsgcx | Xxzr | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Rkkxnjbx | Fgdn | $28.1 Bil | |||
| Moderna Inc
MRNA
| Gdvrdvgc | Pbzmb | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Llwbrdwj | Ymsrs | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ctsmrplsp | Pyvwqq | $13.4 Bil | |||
| Incyte Corp
INCY
| Sghjbpbw | Rfgszty | $12.7 Bil |
United States